VCIM
CATX icon

Velan Capital Investment Management’s Perspective Therapeutics CATX Stock Holding History

Velan Capital Investment Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500,000
Closed -$1.72M – 51
2025
Q2 		$1.72M Hold
500,000
– – 1.7% 17
2025
Q1 		$1.06M Hold
500,000
– – 1.1% 19
2024
Q4 		$1.59M Buy
+500,000
New +$4.08M 1.38% 14

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Velan Capital Investment Management's CATX Position: Q3 2025 in Review

Velan Capital Investment Management sold out of Perspective Therapeutics (CATX) in Q3 2025, closing a stake of 500,000 shares — an estimated $1.72M sold.

Velan Capital Investment Management first reported a position in CATX in Q4 2024 and held it in 3 quarters. The position peaked at $1.72M in Q2 2025. 105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

  • Velan Capital Investment Management reported no remaining Perspective Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 500,000 Perspective Therapeutics shares in Q3 2025, an estimated $1.72M.
  • Velan Capital Investment Management first reported a position in Perspective Therapeutics in Q4 2024 and held it in 3 quarters.
  • Velan Capital Investment Management's Perspective Therapeutics position peaked at $1.72M in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.